Bayer AG

Bayer AG

BAYRY

$14.08

Updated: 24/09/2026, 10:36:21

Market Cap
$55.33B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
DE
Stock valuation chart
One-year closing share-price history for BAYRY
Company Profile

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

USD
OTC
CEO: Bill Anderson
Employees: 88,078
https://www.bayer.com
Asset Summaries
Latest generated summaries for BAYRY

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for BAYRY.
Share price
$14.08
Market cap
$55.33B
Exchange
OTC
Currency
USD
CEO
Bill Anderson
Employees
88,078
IPO date
18/11/1996
Beta
0.833
Last dividend
$0.00
Day range
$14.02 – $14.23
52-week range
$7.48 – $15.23
1-day performance
-0.71%
1-year performance
88.24%
Current drawdown (1Y)
-7.55%
CIK
N/A
CUSIP
072730302
ISIN
US0727303028
Created
07/12/2025, 02:55:36
Last update
24/09/2026, 10:36:21

Track Bayer AG with an AI analyst

See which prediction-market events move BAYRY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BAYRY from your Railway `news_articles` table.